butyl 2-[4-(4-isobutylphenyl)-1H-imidazol-2-yl]ethylcarbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: butyl 2-[4-(4-isobutylphenyl)-1H-imidazol-2-yl]ethylcarbamate
• 英文别名: butyl N-[2-[5-[4-(2-methylpropyl)phenyl]-1H-imidazol-2-yl]ethyl]carbamate
• 化学式: C₂₀H₂₉N₃O₂
• 分子量: 343.469
• InChiKey: PSTZUVCXDOGCSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氯甲酸丁酯 在 sodium hydroxide 、 ammonium acetate 、 caesium carbonate 作用下， 以 乙醇 、 xylene 为溶剂， 反应 17.0h， 生成 butyl 2-[4-(4-isobutylphenyl)-1H-imidazol-2-yl]ethylcarbamate
  参考文献：
  名称：

  Butyl 2-(4-[1.1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain

  摘要：

  A series of 4-arylimidazole carbamates was synthesized and their binding affinities to the site-2 sodium (Na+) channel were determined. SAR studies led to the identification of compound 10, a potent Na+ channel blocker which was efficacious in pain models in vivo. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.064

文献信息

• Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
  申请人：——

  公开号：US20040132788A1

  公开（公告）日：2004-07-08

  The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) 1 wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R 1 and R 2 are notably independently hydrogen, alkyl or cycloalkyl and &OHgr; is —NR 46 R 47 or —OR 48 R 46 and R 47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH 2 ) k —COOR 51 , R 51 is notably alkyl or haloalkyl and R 48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.

  本发明涉及噻唑、噁唑、咪唑、异噁唑和异噁唑啉的一般式(I)衍生物，其中Het为噻唑、噁唑、咪唑、异噁唑或异噁唑啉，n为0至6的整数，A特别选自各种可任选取代的芳香族基团，B特别为氢、烷基或苯基，R1和R2特别独立地为氢、烷基或环烷基，Ω为—NR46R47或—OR48，R46和R47特别独立地为氢、烷基、环烷基或—(CH2)k—COOR51，R51特别为烷基或卤代烷基，R48特别为氢或烷基。这些化合物具有有利的药理学特性，使其可用于治疗学，特别是用于治疗神经退行性疾病或疼痛。
• DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：CHABRIER DE LASSAUNIERE Pierre-Etienne

  公开号：US20110172434A1

  公开（公告）日：2011-07-14

  The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R 1 and R 2 are notably independently hydrogen, alkyl or cycloalkyl and Ω is —NR 46 R 47 or —OR 48 , R 46 and R 47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH 2 ) k —COOR 51 , R 51 is notably alkyl or haloalkyl and R 48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.

  本发明涉及通式（I）的噻唑，噁唑，咪唑，异噁唑和异噁唑啉衍生物，其中Het为噻唑，噁唑，咪唑，异噁唑或异噁唑啉，n为0至6的整数，A特别选择自各种可选取代的芳香基团，B特别为氢，烷基或苯基，R1和R2特别独立地为氢，烷基或环烷基，Ω为—NR46R47或—OR48，R46和R47特别独立地为氢，烷基，环烷基或—(CH2)k—COOR51，R51特别为烷基或卤代烷基，R48特别为氢或烷基。这些化合物具有有利的药理学性质，可以在治疗中使用，特别用于治疗神经退行性疾病或疼痛。
• DERIVES D'HETEROCYCLES A 5 CHAINONS, LEUR PREPARATION ET LEUR APPLICATION COMME MEDICAMENTS
  申请人：IPSEN PHARMA

  公开号：EP1379514B1

  公开（公告）日：2009-07-15
• US7291641B2
  申请人：——

  公开号：US7291641B2

  公开（公告）日：2007-11-06
• US7956075B2
  申请人：——

  公开号：US7956075B2

  公开（公告）日：2011-06-07